Research programme: bacteriophage therapeutics - AmpliPhi BioSciences/Leicester & Glasgow Universities

Drug Profile

Research programme: bacteriophage therapeutics - AmpliPhi BioSciences/Leicester & Glasgow Universities

Alternative Names: AB CD01; AmpliPhage-004

Latest Information Update: 23 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AmpliPhi Biosciences Corporation; University of Glasgow; University of Leicester
  • Class Antibacterials; Bacteriophages
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Clostridium-difficile-infections

Most Recent Events

  • 12 Sep 2016 Preclinical trials in Clostridium difficile infections (Prevention) in United Kingdom (unspecified route) before September 2016
  • 12 Sep 2016 Preclinical trials in Clostridium difficile infections in United Kingdom (unspecified route) before September 2016
  • 12 Sep 2016 Antimicrobial data from a preclinical study released by AmpliPhi Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top